Hormonal
Canagliflozin (100 mg and 300 mg) significantly reduces HbA1c, body weight, and systolic blood pressure in patients with type 2 diabetes on background metformin compared to placebo and sitagliptin.
If you have type 2 diabetes and are already taking metformin, adding canagliflozin (100mg or 300mg daily) can significantly lower your blood sugar, help you lose weight, and reduce blood pressure compared to placebo or sitagliptin. While there is a slightly higher risk of genital yeast infections and urinary frequency, these are usually mild and rarely cause people to stop the medication. Hypoglycemia risk remains low.
At week 26, canagliflozin 100 mg and 300 mg reduced HbA1c vs placebo... Canagliflozin 100 mg and 300 mg reduced body weight vs placebo... and sitagliptin... Both canagliflozin doses reduced FPG and systolic BP vs placebo... and sitagliptin
Why this rating
Phase 3, randomised, double-blind, placebo- and active-controlled trial with 1,284 participants.
Source
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
Fernando J. Lavalle‐González et al. · Diabetologia · 2013
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →